CB-03-01
CB-03-01, a molecule patented by Cosmo, is a steroidal ester, androgen antagonist derived from 11-deoxycortisone, which tightly mimics the profile of an ideal anti-androgen for topical use.
The objective is to create a product for topical application to treat acne, male pattern baldness, and seborrhoea that does not have the side effects of products currently being taken in tablet form.
An IND was filed in the US for CB-03-01 for acne. Clinical trials are planned to start in the USA in Q2 2012.
Cosmo's patents expire in the year 2022 and 2028.